RALEIGH, N.C.--(BUSINESS WIRE)--May 22, 2006--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP - News) today announced results of one investigator-initiated trial of XIFAXAN® (rifaximin) tablets 200 mg and one investigator-initiated trial of COLAZAL® (balsalazide disodium) Capsules 750 mg that were presented Sunday, May 21 at Digestive Disease Week® 2006.
